Expanding the criteria for BRCA mutation testing in breast cancer survivors

Journal of Clinical Oncology

Volumn 28, Issue 27, 2010, Pages 4214-4220

  Kwon, Janice S ^a   Gutierrez Barrera, Angelica M ^a   Young, Diana ^a   Sun, Charlotte C ^a   Daniels, Molly S ^a   Lu, Karen H ^a   Arun, Banu ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; BLID PROTEIN, HUMAN; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SURVIVOR; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENETIC SCREENING; GROUPS BY AGE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; BREAST TUMOR; COMPUTER SIMULATION; ECONOMICS; GENETICS; HEALTH CARE COST; MIDDLE AGED; MONTE CARLO METHOD; MORTALITY; MUTATION; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION AND FORECASTING; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FEMALE; GENETIC TESTING; HEALTH CARE COSTS; HUMANS; LIFE EXPECTANCY; MIDDLE AGED; MODELS, ECONOMIC; MONTE CARLO METHOD; MUTATION; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957967823     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.0719     Document Type: Article

References (91)

1. American Cancer Society: Breast Cancer Facts & Figures 2003-2004. Atlanta, GA, Department of Epidemiology and Surveillance Research, 2003, pp 1-27
2. Anderson WF, Pfeiffer RM, Dores GM, et al: Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 15:1899-1905, 2006
3. Gloeckler Ries LA, Eisner MP: SEER Survival Monograph: Cancer of the Female Breast, in National Cancer Institute Surveillance Research Program (ed): SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, MD, pp 101-110, 2007
4. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20:1480-1490, 2002 (Pubitemid 34260526)
5. Papelard H, de Bock GH, van Eijk R, et al: Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br J Cancer 83:719-724, 2000
6. Thirthagiri E, Lee SY, Kang P, et al: Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res 10:R59, 2008
7. Weitzel JN, Lagos VI, Cullinane CA, et al: Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 297:2587-2595, 2007 (Pubitemid 46961030)
8. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389-1399, 2001
9. Pharoah PD, Lipscombe JM, Redman KL, et al: Familial predisposition to breast cancer in a British population: Implications for prevention. Eur J Cancer 36:773-779, 2000 (Pubitemid 30179750)
10. Ziogas A, Gildea M, Cohen P, et al: Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 9:103-111, 2000 (Pubitemid 30062916)
11. American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol 21:2397-2406, 2003
12. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. Ann Intern Med 143:355-361, 2005
13. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113:957-966, 2009
14. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
15. Kandel MJ, Stadler Z, Masciari S, et al: Prevalence of BRCA1 mutations in triple negative breast cancer. J Clin Oncol 24:5s, 2006 (abstr 508)
16. Eisinger F, Jacquemier J, Charpin C, et al: Mutations at BRCA1: The medullary breast carcinoma revisited. Cancer Res 58:1588-1592, 1998 (Pubitemid 28215075)
17. Iau PT, Marafie M, Ali A, et al: Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer. Breast Cancer Res Treat 85:81-88, 2004 (Pubitemid 38437984)
18. Pohlreich P, Zikan M, Stribrna J, et al: High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res 7:R728-736, 2005
19. Neumann PJ, Sandberg EA, Bell CM, et al: Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 19:92-109, 2000
20. Weinstein MC, Siegel JE, Gold MR, et al: Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276:1253-1258, 1996 (Pubitemid 26337709)
21. Graeser MK, Engel C, Rhiem K, et al: Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:5887-5892, 2009
22. Metcalfe K, Lynch HT, Ghadirian P, et al: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328-2335, 2004 (Pubitemid 41115389)
23. Pierce LJ, Levin AM, Rebbeck TR, et al: Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24:2437-2443, 2006 (Pubitemid 46630619)
24. Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al: Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17:391-400, 2006 (Pubitemid 43329574)
25. El-Tamer M, Russo D, Troxel A, et al: Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol 11:157-164, 2004 (Pubitemid 40486790)
26. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115-123, 2007 (Pubitemid 47057729)
27. Robson ME, Chappuis PO, Satagopan J, et al: A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8-R17, 2004
28. Boyd J, Sonoda Y, Federici MG, et al: Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260-2265, 2000 (Pubitemid 30246777)
29. Cass I, Baldwin RL, Varkey T, et al: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187-2195, 2003 (Pubitemid 36444059)
30. Kosary CL: Cancer of the ovary, in Ries LAG YJ, Keel GE, Eisner MP, (eds): SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program. Bethesda, MD, National Institutes of Health, 2007, pp 133-144
31. Rubin SC, Benjamin I, Behbakht K, et al: Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335:1413-1416, 1996 (Pubitemid 26382501)
32. Herrinton LJ, Barlow WE, Yu O, et al: Efficacy of prophylactic mastectomy in women with unilateral breast cancer: A cancer research network project. J Clin Oncol 23:4275-4286, 2005 (Pubitemid 46207002)
33. Kaas R, Verhoef S, Wesseling J, et al: Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: Very low risk for subsequent breast cancer. Ann Surg 251:488-492, 2010
34. van Sprundel TC, Schmidt MK, Rookus MA, et al: Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93:287-292, 2005 (Pubitemid 43080030)
35. Hartmann LC, Sellers TA, Schaid DJ, et al: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633-1637, 2001 (Pubitemid 33094870)
36. Finch A, Beiner M, Lubinski J, et al: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296:185-192, 2006
37. Kauff ND, Domchek SM, Friebel TM, et al: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. J Clin Oncol 26:1331-1337, 2008
38. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002 (Pubitemid 34755669)
39. Botkin JR, Smith KR, Croyle RT, et al: Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118:201-209, 2003 (Pubitemid 37063927)
40. Bradbury AR, Ibe CN, Dignam JJ, et al: Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med 10:161-166, 2008
41. Foster C, Watson M, Eeles R, et al: Predictive genetic testing for BRCA1/2 in a UK clinical cohort: Three-year follow-up. Br J Cancer 96:718-724, 2007 (Pubitemid 46376618)
42. Friebel TM, Domchek SM, Neuhausen SL, et al: Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer 7:875-882, 2007
43. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al: Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355:2015-2020, 2000 (Pubitemid 30339238)
44. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122:2017-2022, 2008 (Pubitemid 351441190)
45. SEER: SEER Relative Survival Rates for Breast Cancer, SEER 9 Registries for 1988-2003, 2007
46. Arias E: United States Life Tables, 2004, in National Vital Statistics Reports, Vol 56, No. 9. Hyattsville, MD, National Center for Health Statistics, 2007
47. Pal T, Permuth-Wey J, Betts JA, et al: BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104:2807-2816, 2005 (Pubitemid 41798292)
48. Risch HA, McLaughlin JR, Cole DE, et al: Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694-1706, 2006 (Pubitemid 44942707)
49. Risch HA, McLaughlin JR, Cole DE, et al: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700-710, 2001 (Pubitemid 32203724)
50. SEER: Cancer Stat Fact Sheets: Cancer of the Ovary. http://seer.cancer. gov/statfacts/html/ovary.html
51. Hospital and Ambulatory Surgery Care for Women's Cancers: Health Care Cost and Utilization Project Highlight, Issue 2, No. 06-0038. Rockville, MFD, Agency for Healthcare Research and Quality, 2006
52. Gloeckler Ries LA, Eisner MP: Cancer of the Female Breast. Bethesda, MD, National Cancer Institute, SEER Survival Monograph, 2002, pp 101-110
53. Bauer KR, Brown M, Cress RD, et al: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer 109:1721-1728, 2007 (Pubitemid 46668532)
54. SEER: Cancer Stat Fact Sheets: Cancer of the Breast. http://seer.cancer. gov/statfacts/html/breast.html
55. Loman N, Johannsson O, Kristoffersson U, et al: Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 93:1215-1223, 2001 (Pubitemid 32816196)
56. Tereschenko IV, Basham VM, Ponder BA, et al: BRCA1 and BRCA2 mutations in Russian familial breast cancer. Hum Mutat 19:184, 2002
57. Whittemore AS, Gong G, Itnyre J: Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 60:496-504, 1997 (Pubitemid 27097597)
58. Perkins CI, Morris CR, Wright WE, et al: Cancer Incidence and Mortality in California by Detailed Race/Ethnicity, 1998-1992. Sacramento, CA, Department of Health Services, Cancer Surveillance Section, 2002
59. Metcalfe KA, Lynch HT, Ghadirian P, et al: The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 96:222-226, 2005 (Pubitemid 39612440)
60. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003 (Pubitemid 36530000)
61. Metcalfe KA, Lubinski J, Ghadirian P, et al: Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: The Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 26:1093-1097, 2008
62. Fryback DG, Dasbach EJ, Klein R, et al: The Beaver Dam Health Outcomes Study: Initial catalog of health-state quality factors. Med Decis Making 13:89-102, 1993 (Pubitemid 23113445)
63. Grann VR, Jacobson JS, Sundararajan V, et al: The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations. Cancer J Sci Am 5:283-292, 1999 (Pubitemid 29471533)
64. Sun CC, Bodurka-Bevers D, Cantor SB, et al: Preferences for outcomes in women at high-risk for breast/ovarian cancer - who and how you ask matters. Proc Am J Clin Oncol 19:435a, 2000 (abstr 5556)
65. Tengs TO, Winer EP, Paddock S, et al: Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: A decision analysis. Med Decis Making 18:365-375, 1998 (Pubitemid 28465276)
66. van Roosmalen MS, Verhoef LC, Stalmeier PF, et al: Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: A more prominent role for oophorectomy. J Clin Oncol 20:2092-2100, 2002 (Pubitemid 34408800)
67. Tengs TO, Wallace A: One thousand health-related quality-of-life estimates. Med Care 38:583-637, 2000
68. Lidgren M, Wilking N, Jonsson B, et al: Health related quality of life in different states of breast cancer. Qual Life Res 16:1073-1081, 2007 (Pubitemid 47174889)
69. Lloyd A, Nafees B, Narewska J, et al: Health state utilities for metastatic breast cancer. Br J Cancer 95:683-690, 2006 (Pubitemid 44373482)
70. Department of State Health Services, Austin, Texas: FY08 Monthly Title V Genetic Services Procedure Code Report: Women and Infants. http://www.dshs. state.tx.us/genetics/doc/ProcedureCodeReportForm08.doc
71. Myriad: Myriad Genetic Laboratories. http://www.myriadtests.com
72. Reference deleted
73. Merrill CT, Elixhauser A: Hospitalization in the United States, 2002, in Health Care Cost and Utilization Fact Book 6, No. 05-0056. Rockville, MD, Agency for Healthcare Research and Quality, 2005
74. US Department of Labor, Bureau of Labor Statistics: National Compensation Survey: Occupational Earnings in the United States, 2009, Bulletin 2738. http://www.bls.gov/ncs/ncswage2009.htm
75. Wright JC, Weinstein MC: Gains in life expectancy from medical interventions-standardizing data on outcomes. N Engl J Med 339:380-386, 1998 (Pubitemid 28363802)
76. Lerman C, Hughes C, Croyle RT, et al: Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31:75-80, 2000 (Pubitemid 30471180)
77. Lodder L, Frets PG, Trijsburg RW, et al: Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing. Am J Med Genet A 119A:266-272, 2003 (Pubitemid 37063852)
78. Scheuer L, Kauff N, Robson M, et al: Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1268, 2002 (Pubitemid 34177432)
79. Schwartz MD, Kaufman E, Peshkin BN, et al: Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 21:4034-4041, 2003 (Pubitemid 46606219)
80. Evans GR, Gaarenstroom KN, Stirling D, et al: Screening for familial ovarian cancer: Poor survival of BRCA1/2 related cancers. J Med Genet 46:593-597, 2009
81. Hermsen BB, Olivier RI, Verheijen RH, et al: No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 96:1335-1342, 2007 (Pubitemid 46685786)
82. Stirling D, Evans DG, Pichert G, et al: Screening for familial ovarian cancer: Failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. J Clin Oncol 23:5588-5596, 2005
83. Brekelmans CT, Seynaeve C, Bartels CC, et al: Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19:924-930, 2001 (Pubitemid 32176266)
84. Kriege M, Brekelmans CT, Boetes C, et al: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427-437, 2004
85. Lehman CD, Blume JD, Weatherall P, et al: Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 103:1898-1905, 2005
86. Stoutjesdijk MJ, Boetes C, Jager GJ, et al: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 93:1095-1102, 2001 (Pubitemid 32717542)
87. Warner E, Plewes DB, Hill KA, et al: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-1325, 2004 (Pubitemid 39223222)
88. Eisen A, Lubinski J, Klijn J, et al: Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study. J Clin Oncol 23:7491-7496, 2005 (Pubitemid 46291812)
89. Rebbeck TR, Friebel T, Lynch HT, et al: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 22:1055-1062, 2004 (Pubitemid 41095038)
90. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
91. Kwon JS, Daniels MS, Sun CC, et al: Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol 28:675-682, 2010